Hello:
What is your opinion regarding the DRAFT GUIDANCE,
ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin?
Do we need to performance a extensive clinical study or a bioequivalence PK is enough?
Thanks in advance!
Alejandra Cruz
Project Leader
------------------------------
Alejandra Cruz
México
------------------------------